Pharmaceutical MDL-2243 Closed • NJ

Fosamax Bone Injury Lawsuit

IN RE: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II)

559

Pending Actions

1,294

Total Actions Filed

57%

Resolution Rate

Active

Status

Updated 2026-10-01

Case Resolution Progress

This long-running pharmaceutical MDL shows active case resolution. The mid-2025 jump reflected reinstated cases, not new filings: federal cases were reinstated after the Third Circuit's September 2024 ruling, and the Supreme Court declined review in June 2025. Since the peak, 413 cases have been resolved, driven by a Master Settlement Agreement signed July 28, 2025.

Jan 25

Feb 25

Mar 25

Apr 25

May 25

950

Jun 25

971

Jul 25

972

Aug 25

972

Sep 25

966

Oct 25

846

Nov 25

845

Dec 25

580

Jan 26

572

Feb 26

564

Mar 26

561

Apr 26

561

May 26

557

Jun 26

557

Jul 26

550

Aug 26

549

Sep 26

562

Oct 26

559

Source: JPML MDL Statistics Reports, January 2025-October 2026

Overview

The Fosamax (Alendronate Sodium) MDL consolidates lawsuits against Merck involving the osteoporosis drug Fosamax. Plaintiffs allege the medication causes atypical femur fractures (thigh bone breaks).

As of 2026-10-01, there are 559 pending actions out of 1,294 total actions filed, representing a 57% resolution rate.

A Master Settlement Agreement was signed on July 28, 2025 with plaintiffs' lawyers in the New Jersey state and federal cases. It requires at least 95% participation. A California settlement agreement followed on February 18, 2026.

Who May Qualify

Eligibility for this MDL typically depends on factors such as:

History of taking Fosamax (alendronate sodium) for osteoporosis
Diagnosis of an atypical femur fracture
Medical records documenting Fosamax use and subsequent femur fracture

Key Information

Assigned Judge

Karen M. Williams (U.S. District Judge)

District Court

District of New Jersey

MDL Number

MDL-2243